Standard BioTools announced two major transactions: a deal to sell its mass cytometry business to Multiplex Bio and a separate settlement with Illumina. The sale provides a $5 million promissory note at 6% interest maturing in five years, plus up to $5 million in contingent consideration, and may include up to a $10 million company-funded working capital loan if third-party financing is unavailable. In a distinct agreement, Standard BioTools received approximately $30 million from Illumina in exchange for waiving a 2026 earnout and terminating certain SOMAmer-related royalty and licensing agreements. These actions monetize contingent assets, simplify IP relationships, and streamline the company’s portfolio ahead of its pending Treeline merger.

Agreement 1: Standard BioTools Receives $30 Million From Illumina to End Earnout, Royalty and Licensing Obligations

  • Agreement type: Termination, Waiver and Release Agreement (monetization of earnout and royalties)
  • Counterparty: Illumina
  • Signed / Effective: Jul 24 2026 / Jul 24 2026

Agreement 2: Standard BioTools to Sell Mass Cytometry Business to Multiplex Bio for $5 Million Note

  • Agreement type: Share and Asset Purchase Agreement (sale of mass cytometry business)
  • Counterparty: Multiplex Bio
  • Signed / Effective: Jul 28 2026 / Upon closing
  • Duration / Termination: Until closing
  • Reason: Divest non-core unit and streamline ahead of Treeline merger

Agreement 3: Standard BioTools Ends SOMAmer NGS Kit Royalty Agreement With Illumina for $30 Million

  • Agreement terminated: Royalty agreement on SOMAmer-based NGS library preparation kits
  • Counterparty: Illumina
  • Original agreement date: Jan 30 2026
  • Termination date: Jul 24 2026
  • Termination type: mutual
  • Exit fees / payments: $30,000,000 cash received
  • Reason: Monetize royalties and simplify ongoing obligations

Agreement 4: Standard BioTools Terminates Single SOMAmer License From Illumina as Part of $30 Million Deal

  • Agreement terminated: License agreement for Single SOMAmer intellectual property
  • Counterparty: Illumina
  • Original agreement date: Jan 30 2026
  • Termination date: Jul 24 2026
  • Termination type: mutual
  • Exit fees / payments: $30,000,000 cash received
  • Reason: Streamline IP arrangements and monetize value upfront

Agreement 5: Standard BioTools Ends Single SOMAmer Royalty Agreement With Illumina for $30 Million

  • Agreement terminated: Royalty agreement on Single SOMAmers
  • Counterparty: Illumina
  • Original agreement date: Jan 30 2026
  • Termination date: Jul 24 2026
  • Termination type: mutual
  • Exit fees / payments: $30,000,000 cash received
  • Reason: Monetize future royalties and simplify obligations

Agreement 6: Standard BioTools Waives 2026 Illumina Earnout Right in $30 Million Settlement

  • Agreement terminated: 2026 earnout right under the Illumina Stock Purchase Agreement
  • Counterparty: Illumina
  • Original agreement date: Jun 22 2025
  • Termination date: Jul 24 2026
  • Termination type: mutual
  • Exit fees / payments: $30,000,000 cash received
  • Reason: Accelerate value and eliminate contingent payments

Original SEC Filing:

This is an AI-powered summary. It may contain inaccuracies. Consider verifying important information with the source. Please note this summary is solely based on documents filed with the SEC.